modelPeginterferonBeta1a
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB13.
Information
| name: | PeginterferonBeta1a | |
| ATC code: | L03AB13 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 125 | mg |
| volume of distribution: | 4.7 | L |
| clearance: | 0.15 | L/h |
| other parameters in model implementation | ||
Peginterferon beta-1a is a pegylated form of interferon beta-1a approved for the treatment of relapsing forms of multiple sclerosis (MS). The PEGylation increases the half-life, allowing for less frequent dosing compared to conventional interferon beta-1a preparations. It is currently approved and in clinical use.
Pharmacokinetics
Pharmacokinetic parameters are reported for adult patients with relapsing-remitting MS. Most data are from healthy subjects and MS patients administered a subcutaneous dose of 125 micrograms every 2 weeks.
References
Zhao, Y, et al., & Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. Med (New York, N.Y.) 3(9) 612–621.e3. DOI:10.1016/j.medj.2022.06.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35853458
Hoy, SM (2015). Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS drugs 29(2) 171–179. DOI:10.1007/s40263-015-0227-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25666445
Hu, X, et al., & Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. British journal of clinical pharmacology 82(2) 380–388. DOI:10.1111/bcp.12968 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27060836
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)